Dolutegravir/rilpivirine

< Dolutegravir

Dolutegravir/rilpivirine
Combination of
DolutegravirHIV integrase strand transfer inhibitor (INSTI)
RilpivirineHIV non-nucleoside reverse-transcriptase inhibitor (NNRTI)
Clinical data
Trade namesJuluca
AHFS/Drugs.comMonograph
License data
Pregnancy
category
  • AU: B1
Routes of
administration		By mouth
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • CA: ℞-only
  • UK: POM (Prescription only)
  • US: ℞-only
  • EU: Rx-only
  • In general: ℞ (Prescription only)
Identifiers
KEGG

Dolutegravir/rilpivirine, sold under the brand name Juluca, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. It contains the medicines dolutegravir and rilpivirine. It is taken by mouth.

The most common adverse reactions (of all severity grades) are diarrhea and headache.

Dolutegravir/rilpivirine was approved for use in the United States in November 2017, and for use in the European Union in May 2018.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.